Immunovant Statistics

Total Valuation

Immunovant has a market cap or net worth of $3.71 billion. The enterprise value is $3.07 billion.

Market Cap	3.71B
Enterprise Value	3.07B

Important Dates

The next estimated earnings date is Friday, June 7, 2024, before market open.

Earnings Date	Jun 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Immunovant has 146.05 million shares outstanding. The number of shares has increased by 12.21% in one year.

Shares Outstanding	146.05M
Shares Change (YoY)	+12.21%
Shares Change (QoQ)	+0.79%
Owned by Insiders (%)	55.23%
Owned by Institutions (%)	48.21%
Float	64.52M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	6.00
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 13.70, with a Debt / Equity ratio of 0.00.

Current Ratio	13.70
Quick Ratio	13.18
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -56.10% and return on invested capital (ROIC) is -45.75%.

Return on Equity (ROE)	-56.10%
Return on Assets (ROA)	-51.30%
Return on Capital (ROIC)	-45.75%
Revenue Per Employee	n/a
Profits Per Employee	-$1.58M
Employee Count	164
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Immunovant has paid $567,000 in taxes.

Income Tax	567,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +20.85% in the last 52 weeks. The beta is 0.75, so Immunovant's price volatility has been lower than the market average.

Beta (1Y)	0.75
52-Week Price Change	+20.85%
50-Day Moving Average	29.78
200-Day Moving Average	33.00
Relative Strength Index (RSI)	31.54
Average Volume (30 Days)	1,162,588

Short Selling Information

The latest short interest is 9.29 million, so 6.36% of the outstanding shares have been sold short.

Short Interest	9.29M
Short Previous Month	8.96M
Short % of Shares Out	6.36%
Short % of Float	14.39%
Short Ratio (days to cover)	9.09

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-282.71M
Pretax Income	-258.77M
Net Income	-259.34M
EBITDA	-257.41M
EBIT	-258.77M
Earnings Per Share (EPS)	-$1.88

Full Income Statement

Balance Sheet

The company has $635.37 million in cash and $138,000 in debt, giving a net cash position of $635.23 million or $4.35 per share.

Cash & Cash Equivalents	635.37M
Total Debt	138,000
Net Cash	635.23M
Net Cash Per Share	$4.35
Equity / Book Value	617.76M
Book Value Per Share	4.23
Working Capital	617.16M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$214.23 million and capital expenditures -$360,000, giving a free cash flow of -$214.59 million.

Operating Cash Flow	-214.23M
Capital Expenditures	-360,000
Free Cash Flow	-214.59M
FCF Per Share	-$1.55

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immunovant does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.21%
Shareholder Yield	-12.21%
Earnings Yield	-6.99%
FCF Yield	-5.79%

Dividend Details

Analyst Forecast

The average price target for Immunovant is $48.20, which is 89.84% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$48.20
Price Target Difference	89.84%
Analyst Consensus	Strong Buy
Analyst Count	16
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2